Logo image of OCX

ONCOCYTE CORP (OCX) Stock Fundamental Analysis

NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD

2.65  -0.07 (-2.57%)

Fundamental Rating

1

OCX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. OCX has a bad profitability rating. Also its financial health evaluation is rather negative. OCX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OCX has reported negative net income.
In the past year OCX has reported a negative cash flow from operations.
OCX had negative earnings in each of the past 5 years.
In the past 5 years OCX always reported negative operating cash flow.
OCX Yearly Net Income VS EBIT VS OCF VS FCFOCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

OCX has a Return On Assets (-62.11%) which is in line with its industry peers.
OCX's Return On Equity of -449.08% is on the low side compared to the rest of the industry. OCX is outperformed by 79.40% of its industry peers.
Industry RankSector Rank
ROA -62.11%
ROE -449.08%
ROIC N/A
ROA(3y)-50.62%
ROA(5y)-52.42%
ROE(3y)-131.98%
ROE(5y)-111.62%
ROIC(3y)N/A
ROIC(5y)N/A
OCX Yearly ROA, ROE, ROICOCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

OCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCX Yearly Profit, Operating, Gross MarginsOCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCX has more shares outstanding
OCX has more shares outstanding than it did 5 years ago.
OCX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OCX Yearly Shares OutstandingOCX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
OCX Yearly Total Debt VS Total AssetsOCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -7.87, we must say that OCX is in the distress zone and has some risk of bankruptcy.
OCX's Altman-Z score of -7.87 is on the low side compared to the rest of the industry. OCX is outperformed by 69.80% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that OCX is not too dependend on debt financing.
OCX has a worse Debt to Equity ratio (0.07) than 64.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -7.87
ROIC/WACCN/A
WACC9.44%
OCX Yearly LT Debt VS Equity VS FCFOCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 0.53 indicates that OCX may have some problems paying its short term obligations.
OCX has a Current ratio of 0.53. This is amonst the worse of the industry: OCX underperforms 92.90% of its industry peers.
A Quick Ratio of 0.50 indicates that OCX may have some problems paying its short term obligations.
OCX has a worse Quick ratio (0.50) than 92.90% of its industry peers.
Industry RankSector Rank
Current Ratio 0.53
Quick Ratio 0.5
OCX Yearly Current Assets VS Current LiabilitesOCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.58% over the past year.
OCX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -51.44%.
The Revenue has been growing slightly by 7.20% on average over the past years.
EPS 1Y (TTM)51.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.99%
Revenue 1Y (TTM)-51.44%
Revenue growth 3Y7.2%
Revenue growth 5YN/A
Sales Q2Q%-73.19%

3.2 Future

The Earnings Per Share is expected to grow by 17.45% on average over the next years. This is quite good.
The Revenue is expected to grow by 55.61% on average over the next years. This is a very strong growth
EPS Next Y20.01%
EPS Next 2Y23.72%
EPS Next 3Y17.45%
EPS Next 5YN/A
Revenue Next Year-66.95%
Revenue Next 2Y-17.42%
Revenue Next 3Y55.61%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OCX Yearly Revenue VS EstimatesOCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
OCX Yearly EPS VS EstimatesOCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCX Price Earnings VS Forward Price EarningsOCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCX Per share dataOCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

OCX's earnings are expected to grow with 17.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.72%
EPS Next 3Y17.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOCYTE CORP

NASDAQ:OCX (2/21/2025, 8:00:01 PM)

2.65

-0.07 (-2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)04-10 2025-04-10/amc
Inst Owners66.6%
Inst Owner Change-97.99%
Ins Owners1.25%
Ins Owner Change24.58%
Market Cap55.81M
Analysts74.29
Price Target4.21 (58.87%)
Short Float %1.97%
Short Ratio3.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.15%
Min EPS beat(2)-122.54%
Max EPS beat(2)36.24%
EPS beat(4)1
Avg EPS beat(4)-59.58%
Min EPS beat(4)-122.54%
Max EPS beat(4)36.24%
EPS beat(8)4
Avg EPS beat(8)-49.79%
EPS beat(12)8
Avg EPS beat(12)-25.9%
EPS beat(16)10
Avg EPS beat(16)-18.01%
Revenue beat(2)0
Avg Revenue beat(2)-55.37%
Min Revenue beat(2)-67.67%
Max Revenue beat(2)-43.07%
Revenue beat(4)0
Avg Revenue beat(4)-40.69%
Min Revenue beat(4)-67.67%
Max Revenue beat(4)-1.82%
Revenue beat(8)2
Avg Revenue beat(8)-24.59%
Revenue beat(12)2
Avg Revenue beat(12)-51.61%
Revenue beat(16)4
Avg Revenue beat(16)-40.17%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)5.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-60%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-24.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.72
P/FCF N/A
P/OCF N/A
P/B 5.75
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.59
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0.03
BVpS0.46
TBVpS-2.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.11%
ROE -449.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.62%
ROA(5y)-52.42%
ROE(3y)-131.98%
ROE(5y)-111.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.62%
Cap/Sales 79.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.53
Quick Ratio 0.5
Altman-Z -7.87
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)51.15%
Cap/Depr(5y)147.88%
Cap/Sales(3y)191.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.99%
EPS Next Y20.01%
EPS Next 2Y23.72%
EPS Next 3Y17.45%
EPS Next 5YN/A
Revenue 1Y (TTM)-51.44%
Revenue growth 3Y7.2%
Revenue growth 5YN/A
Sales Q2Q%-73.19%
Revenue Next Year-66.95%
Revenue Next 2Y-17.42%
Revenue Next 3Y55.61%
Revenue Next 5YN/A
EBIT growth 1Y-906.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.29%
EBIT Next 3Y-5.13%
EBIT Next 5YN/A
FCF growth 1Y56.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.64%
OCF growth 3YN/A
OCF growth 5YN/A